Company Information

  

Address: 87 CAMBRIDGE PARK DRIVE  
City: CAMBRIDGE 
State: MA 
Zip Code: 02140 
Telephone: (617) 401-4060 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical-stage biopharmaceutical company using our proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system. Inappropriate activation of the complement system can quickly turn it from a beneficial defense system to an aggressor that plays a major role in immune and inflammatory diseases. The complement system, which consists of approximately 30 interacting proteins, offers a target-rich opportunity for us to leverage our proprietary peptide chemistry platform, which was pioneered by Nobel Laureate Dr. Jack Szostak and allows us to inhibit certain uncontrolled complement pathway factors involved in complement-mediated diseases.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-2.52NAN/E
12/2017-2.41NAN/E
09/201724.01NA0.61
06/201710.28NA1.82
03/20171.94NA10.97
12/2016-6.98NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.28Total Liab/Total Assets0.14
Net Inc/Total Assets-0.68Total Liab/Inv Cap0.15
Net Inc/Inv Cap-0.76Total Liab/Comm Equity0.06
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio8.46
Inventory TurnoverNACurrent Ratio8.46
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) NA 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 3.31 2.68 2.28 2.35
Operating Income -16.72 -15.32 -15.41 -12.81
Interest Exp NA 0.00 NA NA
Pretax Income -16.50 -15.16 -15.28 -12.66
Other Income 0.23 0.16 0.14 0.15
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -16.50 -15.14 -15.28 -12.66

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 109.12 70.38 84.09 96.61
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 110.86 72.88 85.21 97.84
Net Property, Plant & Equipment 5.62 5.61 5.97 6.24
Total Assets 118.18 80.20 92.91 105.82
Liabilities        
Accounts Payable 6.77 8.29 7.37 6.58
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 7.22 8.61 7.80 7.00
Long-Term Debt NA NA NA NA
Total Liabilities 9.50 11.01 10.33 9.65
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.03 0.02 0.02 0.02
Retained Earnings -139.71 -123.21 -108.07 -92.80
Treasury Stock NA NA NA NA
Total Stockholders' Equity 108.68 69.18 82.58 96.18
Total Liabilities and Stockholders' Equity 118.18 80.20 92.91 105.82

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities -15.52 -13.65 -12.21 -8.91
Net Cash Provided by Investing Activities -0.03 -0.02 -0.26 -0.65
Net Cash Provided by Financing Activities 54.29 -0.04 -0.04 0.79

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20144.83-5.48--
12/20154.09-13.94--
12/20164.93-28.86-6.98
12/20170.00-54.44-2.41
Growth Rates-100.00----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/188724,38175.51




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.